创了新高，NSCLC实体瘤继续。TIL。网页链接。

IOVA announced that the FDA lifted a partial clinical hold placed on the registrational IOV-LUN-202 trial investigating LN-145 TIL cell therapy in non-small cell lung cancer (NSCLC). Iovance expects to complete enrollment of approximately 120 patients in the IOV-LUN-202 registrational cohorts in 2025$Iovance(IOVA)$